First-line Zepzelca plus Tecentriq led to survival enhancements versus Tecentriq alone in sufferers with ES-SCLC: © inventory.adobe.com.
Amongst sufferers with extensive-stage small cell lung most cancers (ES-SCLC), first-line upkeep remedy with Zepzelca (lurbinectedin) mixed with Tecentriq (atezolizumab) led to enhancements in each progression-free survival (PFS) and total survival (OS) in contrast with Tecentriq alone, in keeping with main findings from the part 3 IMforte trial which had been shared on the 2025 ASCO Annual Assembly.
The median PFS with the doublet (242 sufferers handled) was 5.4 months by impartial overview facility (IRF) evaluation versus 2.1 months with the monotherapy (241 sufferers handled), translating to a 46% discount within the threat of illness development or demise. The six-month IRF-PFS charges within the respective arms had been 41.2% and 18.7%; at 12 months, these charges had been 20.5% and 12.0%.
A clinically significant OS profit was additionally noticed with the addition of Zepzelca to Tecentriq versus Tecentriq alone, at a median of 13.2 months versus 10.6 months, respectively. The 12-month OS price with the doublet was 56.3% versus 44.1% with the monotherapy.
“IMforte is the primary part 3 research to point out PFS and OS enchancment with first-line upkeep remedy for ES-SCLC, highlighting the potential of Zepzelca plus Tecentriq to grow to be a brand new customary of care [SOC] for first-line upkeep remedy in sufferers with this aggressive and difficult-to-treat illness,” Dr. Luis Paz-Ares, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Most cancers Unit, Universidad Complutense and Ciberonc, in Madrid, Spain, mentioned in a press briefing forward of the assembly.
Underscoring the Unmet Want
Glossary
Total survival (OS): the size of time from both the date of prognosis or the beginning of remedy for a illness that sufferers recognized are alive.
Development-free survival (PFS): the size of time throughout and after the remedy {that a} affected person lives with the illness nevertheless it doesn’t worsen.
Total response price (ORR): the proportion of sufferers who’ve a partial or full response to remedy.
ECOG efficiency standing: describes a affected person’s degree of functioning when it comes to their means to take care of themself, each day exercise, and bodily means.
Myelosuppression: the lower in manufacturing of cells accountable for offering immunity, carrying oxygen and regular blood clotting.
Febrile neutropenia: the event of fever, usually with different indicators of an infection, in a affected person with neutropenia.
SCLC represents roughly 15% of all lung most cancers instances, and 70% of those instances are extensive-stage illness, in keeping with Paz-Ares. For these sufferers, SOC remedy is comprised of induction etoposide, platinum, and an immune checkpoint inhibitor (ICI) within the type of Tecentriq or Imfinzi (durvalumab), adopted by upkeep remedy with the identical ICI. Though sufferers reply to induction, many will expertise early illness development and poor survival. Earlier part trials have proven that when Zepzelca is paired with ICIs, it’s energetic with favorable tolerability.
Shining a Gentle on IMforte: Eligibility, Therapy, Finish Factors
The worldwide, open-label, randomized, part 3 trial enrolled sufferers with ES-SCLC who had not beforehand obtained systemic remedy, who didn’t have central nervous system metastases, and who’ve an ECOG efficiency standing of 0 or 1 (660 sufferers). They obtained induction remedy with Tecentriq plus carboplatin and etoposide for 4 cycles each three weeks.
Sufferers had been screened once more and people with an ongoing full response/partial response or steady illness after induction remedy and an ECOG efficiency standing of 0 or 1 went on to obtain upkeep remedy (483 sufferers). These sufferers had been randomly assigned to obtain 1200 mg of intravenous Tecentriq each three weeks with or with out 3.2 mg/m2 of Zepzelca. Therapy continued till illness development or insupportable toxicity.
Notably, no crossover was allowed. Sufferers had been stratified by efficiency standing (zero versus one), lactate dehydrogenase (≤ higher restrict of regular [ULN] versus > ULN), liver metastases at baseline induction (sure versus no), and receipt of prophylactic cranial irradiation (sure versus no).
The trial’s main finish factors had been IRF-PFS and OS, and secondary finish factors comprised investigator-assessed PFS, goal response price, length of response and security. Efficacy was evaluated from randomization into the upkeep part of the design. Investigators assessed security from day certainly one of cycle certainly one of remedy.
Extra Efficacy Revelations
Investigator-assessed PFS aligned with what was reported with regard to IRF evaluation. The median PFS with Zepzelca plus Tecentriq was 5.4 months versus 2.7 months with Tecentriq monotherapy.
Security Highlight
All-cause unwanted side effects had been reported in 97.1% of these on the mix arm versus 80.8% of these on the monotherapy arm, with 38.0% and 22.1% of those respective results being grade 3 (severe; interferes with an individual’s means to do basic items) or 4 (extreme; requires hospitalization). Therapy-related grade 3 or 4 unwanted side effects had been skilled by extra sufferers within the investigative arm versus these within the management arm, at 25.6% versus 5.8%, respectively.
Twelve sufferers who obtained the doublet skilled grade 5 (demise) unwanted side effects versus six sufferers who obtained the monotherapy; they had been remedy associated for 2 sufferers within the investigative arm and one affected person within the management arm. Extra severe unwanted side effects occurred with the doublet versus the monotherapy (31.0% versus 17.1%).
Uncomfortable side effects led to dose interruption or modification of any drug for 38.0% of these within the investigative arm versus 13.8% of these within the management arm; they led to discontinuation of any drug for six.2% and three.3% of sufferers, respectively.
“The protection profile of Zepzelca plus Tecentriq was manageable, with principally low-grade AEs and low remedy discontinuation charges,” Paz-Ares mentioned. “No clinically significant enhance in immune-related [side effects] was noticed [with the addition of Zepzelca],” he famous.
The commonest unwanted side effects skilled by a minimum of 10% of these within the Zepzelca/Tecentriq and Tecentriq-alone arms had been nausea (36.4% verus 4.2%), anemia (31.8% verus 6.7%), fatigue (20.2% verus 7.9%), decreased urge for food (16.9% verus 6.7%), decreased platelet rely (15.3% verus 2.9%), diarrhea (14.0% verus 7.5%), vomiting (13.6% verus 2.5%), asthenia (12.8% verus 6.3%), thrombocytopenia (12.8% verus 1.7%), decreased neutrophil rely (12.8% verus 1.3%), constipation (12.0% verus 6.3%) and neutropenia (10.7% verus 1.7%).
“You see a transparent enhance for these sufferers handled with Zepzelca/Tecentriq, significantly [side effects] associated to the Zepzelca — nausea, vomiting, diarrhea, asthenia, and likewise some extra myelosuppression,” Paz-Ares famous. “Regarding myelosuppression, that was one of many most important issues, we’ve seen febrile neutropenia solely in 1.7% of instances.”
He added that grade 3 or 4 infections and infestations occurred in 6.6% of those that obtained the doublet versus 5.0% of those that got the monotherapy.
Topline Takeaway
“I feel it’s essential to notice that a minimum of in the USA, Zepzelca is FDA authorized within the second-line setting, and so, with the outcomes of this research, we’d anticipate that it will be moved into the first-line upkeep setting — so, shifting it into an earlier line earlier than there may be development on the first-line remedy,” Dr. Julie R. Gralow, chief medical officer and govt vice chairman of ASCO, commented. “The research is essential as a result of each PFS and OS had been elevated. However I might level out, whereas it is a subsequent step, PFS continues to be fairly low in each arms, and we have to work on further methods of advancing this even additional. So, it’s a small subsequent step; it’s extending the time that the tumor doesn’t progress and the period of time that the sufferers reside, however we have to do extra analysis in ES-SCLC, as effectively.”
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
